Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of MCLA-129 in advanced NSCLC and other solid tumors
NL-OMON60277Phase 2Completed
- Sponsor
- Genmab
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pamvatamig in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and Nonhematologic neoplasms (3 arms), sponsored by Genmab. Primary endpoints: Objective response rate, Safety and tolerability and 4 more. Started Jan 2023; status: completed.
02
Drugs
pamvatamig
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60277.